Back to Search
Start Over
μ-Opioid Receptor Is Induced by IL-13 within Lymph Nodes from Patients with Sézary Syndrome
- Source :
- Journal of Investigative Dermatology, Journal of Investigative Dermatology, Nature Publishing Group, 2010, 130 (5), pp.1337-44. ⟨10.1038/jid.2009.433⟩, Journal of Investigative Dermatology, Nature Publishing Group, 2010, 130 (5), pp.1337-1344. ⟨10.1038/jid.2009.433⟩, Journal of Investigative Dermatology, 2010, 130 (5), pp.1337-44. ⟨10.1038/jid.2009.433⟩, Journal of Investigative Dermatology, Nature Publishing Group, 2010, 130 (5), pp.1337-44. 〈10.1038/jid.2009.433〉
- Publication Year :
- 2010
- Publisher :
- HAL CCSD, 2010.
-
Abstract
- International audience; Endogenous opioid peptides mainly produced by neurons are also released by immune cells. They bind to mu- (mu-opioid receptor, MOR), delta-, and kappa-opioid receptors. On the basis of studies on mice showing that MOR is the main mediator of the deleterious effects of opioids on immunity, we wondered whether MOR, absent under normal conditions, is expressed in some pathological situations such as lymphomas. mRNA expression for all three opioid receptors was examined in lymph node biopsy samples from patients with non-Hodgkin's B-cell and T-cell lymphomas. We found that MOR and one of its ligands (enkephalin) are simultaneously expressed almost exclusively in lymph nodes from patients with Sézary cutaneous T cell lymphoma. As MOR was undetectable in circulating malignant T lymphocytes and in normal immune cells, we hypothesized that tumor-released cytokines might induce MOR expression in non-neoplastic lymph node cells. The correlation between mRNA levels of MOR and interleukin-13 (IL-13) within lymph nodes from Sézary patients led us to investigate the ability of IL-13 to upregulate MOR expression in normal immune cell subsets. We found that IL-13 upregulates MOR in activated Langerhans cells. Thus, our data suggest that, under pathological conditions, IL-13 overexpression might allow immune-derived endogenous opioids to down-modulate immune response.
- Subjects :
- CD4-Positive T-Lymphocytes
MESH: Interleukin-13
Skin Neoplasms
MESH : RNA, Messenger
Enkephalin
Biopsy
Receptors, Opioid, mu
Gene Expression
MESH: Lymph Nodes
CD8-Positive T-Lymphocytes
MESH: Monocytes
[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity
Biochemistry
Monocytes
MESH: Biopsy
0302 clinical medicine
[ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology
Opioid receptor
polycyclic compounds
[ SDV.IMM ] Life Sciences [q-bio]/Immunology
[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology
Receptor
Lymph node
Cells, Cultured
MESH : Lymph Nodes
ComputingMilieux_MISCELLANEOUS
Endogenous opioid
MESH: Langerhans Cells
0303 health sciences
Interleukin-13
MESH : Receptors, Opioid, mu
MESH: Dendritic Cells
MESH : Immune Tolerance
MESH: CD4-Positive T-Lymphocytes
MESH : CD8-Positive T-Lymphocytes
MESH: CD8-Positive T-Lymphocytes
3. Good health
medicine.anatomical_structure
[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology
MESH : CD4-Positive T-Lymphocytes
MESH: Sezary Syndrome
[SDV.IMM]Life Sciences [q-bio]/Immunology
Lymph
MESH: Cells, Cultured
MESH: Gene Expression
MESH: Immune Tolerance
[SDV.IMM] Life Sciences [q-bio]/Immunology
medicine.drug_class
MESH : Langerhans Cells
MESH: Receptors, Opioid, mu
Dermatology
Biology
03 medical and health sciences
Immune system
MESH : Cells, Cultured
MESH : Interleukin-13
mental disorders
Immune Tolerance
medicine
Humans
Sezary Syndrome
RNA, Messenger
Opioid peptide
[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology
Molecular Biology
030304 developmental biology
MESH: RNA, Messenger
MESH : Sezary Syndrome
MESH: Humans
MESH: Skin Neoplasms
MESH : Skin Neoplasms
MESH : Humans
Dendritic Cells
Cell Biology
MESH : Gene Expression
MESH : Monocytes
nervous system
Langerhans Cells
MESH : Biopsy
MESH : Dendritic Cells
Immunology
Lymph Nodes
human activities
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 0022202X and 15231747
- Database :
- OpenAIRE
- Journal :
- Journal of Investigative Dermatology, Journal of Investigative Dermatology, Nature Publishing Group, 2010, 130 (5), pp.1337-44. ⟨10.1038/jid.2009.433⟩, Journal of Investigative Dermatology, Nature Publishing Group, 2010, 130 (5), pp.1337-1344. ⟨10.1038/jid.2009.433⟩, Journal of Investigative Dermatology, 2010, 130 (5), pp.1337-44. ⟨10.1038/jid.2009.433⟩, Journal of Investigative Dermatology, Nature Publishing Group, 2010, 130 (5), pp.1337-44. 〈10.1038/jid.2009.433〉
- Accession number :
- edsair.doi.dedup.....f5faeb33c5393895550acba7090a2a6d